


A genome-wide cross-phenotype meta-analysis of the association of blood pressure with migraine

Yanjun Guo ^{1,2,3✉}, Pamela M. Rist^{1,2,3}, Iyas Daghlas^{1,2}, Franco Giulianini¹, The International Headache Genetics Consortium*, The 23andMe Research Team*, Tobias Kurth^{3,4} & Daniel I. Chasman^{1,2✉}

Blood pressure (BP) was inconsistently associated with migraine and the mechanisms of BP-lowering medications in migraine prophylaxis are unknown. Leveraging large-scale summary statistics for migraine ($N_{\text{cases}}/N_{\text{controls}} = 59,674/316,078$) and BP ($N = 757,601$), we find positive genetic correlations of migraine with diastolic BP (DBP, $r_g = 0.11$, $P = 3.56 \times 10^{-06}$) and systolic BP (SBP, $r_g = 0.06$, $P = 0.01$), but not pulse pressure (PP, $r_g = -0.01$, $P = 0.75$). Cross-trait meta-analysis reveals 14 shared loci ($P \leq 5 \times 10^{-08}$), nine of which replicate ($P < 0.05$) in the UK Biobank. Five shared loci (*ITGB5*, *SMG6*, *ADRA2B*, *ANKDD1B*, and *KIAA0040*) are reinforced in gene-level analysis and highlight potential mechanisms involving vascular development, endothelial function and calcium homeostasis. Mendelian randomization reveals stronger instrumental estimates of DBP (OR [95% CI] = 1.20 [1.15-1.25]/10 mmHg; $P = 5.57 \times 10^{-25}$) on migraine than SBP (1.05 [1.03-1.07]/10 mmHg; $P = 2.60 \times 10^{-07}$) and a corresponding opposite effect for PP (0.92 [0.88-0.95]/10 mmHg; $P = 3.65 \times 10^{-07}$). These findings support a critical role of DBP in migraine susceptibility and shared biology underlying BP and migraine.

¹Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA 02215, USA. ²Harvard Medical School, Boston, MA 02115, USA.

³Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA. ⁴Institute of Public Health, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany. *Lists of authors and their affiliations appear at the end of the paper. ✉email: yguo19@bwh.harvard.edu; dchasman@research.bwh.harvard.edu

Migraine is a chronic intermittent neurological disorder affecting up to 14.7% people worldwide and ranks as the second leading cause of disability, responsible for 5.6% of all years lived with disability¹. The link between migraine and the vascular system has been substantiated by an array of physiologic and epidemiologic evidence, including migraine comorbidities with other vascular conditions including stroke, coronary artery disease (CAD)². Recently, additional evidence for vascular involvement in migraine has emerged from genome-wide association studies (GWAS)³. Approximately, 40% (13 of 38) of the genome-wide significant GWAS loci for migraine map near genes with known or suspected vascular functions, including vascular development, endothelial structure, and smooth muscle function. Loci mapping to the *END1/PHACTR1*, *LRP1*, and *FHL5* genes in particular are shared by migraine and CAD or cervical artery dissection^{4,5}.

Blood pressure (BP) has been associated not only with vascular disease but also with migraine⁶. In contrast to highly consistent associations of increased BP with increased susceptibility to vascular disease, associations of BP with migraine are not consistent⁷. For example, some studies have found associations between elevated systolic BP (SBP) or diastolic BP (DBP) and lower prevalence of migraine⁸, whereas some have found inverse associations only for SBP^{9,10}. One study suggested that migraine was associated with higher DBP but lower SBP¹¹. Still other reports focused on pulse pressure (PP), defined as the difference between SBP and DBP, consistently showed an inverse relationship between PP and migraine^{9,11}. The relationship is further complicated by longitudinal studies suggesting that migraine may increase the risk of incident hypertension^{12,13}, whereas BP has been found to be inversely related to onset of headache and migraine¹⁴. Regardless, BP-lowering medications notably provide prophylactic benefit for many migraineurs, and the choice of antihypertensive appears to be related to comorbidities, cost, availability, or side effect profile rather than the specific mechanism of BP-lowering^{15,16}.

Recently developed but widely accepted genetic methods leveraging only GWAS summary statistics may be used to estimate global¹⁷ and local genetic correlation¹⁸ between BP measures (i.e. SBP, DBP, or PP) and migraine. Additional genetic

methods using GWAS summary statistics, including cross-trait meta-analysis¹⁹ and transcriptome-wide association study (TWAS)²⁰, may be used to identify specific shared genetic components and pathophysiology between BP and migraine. Finally, instrumental genetic analysis, i.e. Mendelian randomization (MR), may suggest causality and directionality of effects of BP on migraine, or the reverse, i.e. migraine influences on BP²¹. Therefore, in the current study, we leverage large-scale genetic summary-level data and the preceding genetic methods to gain insight into mechanistic links between BP and migraine.

Our analysis identifies positive overall genetic correlations of migraine with DBP and SBP, but not PP, and evidence of local genetic overlap with BP at certain previously identified migraine loci after accounting for multiple testing. Cross-trait meta-analysis reveals shared loci between BP and migraine, some of which are also reinforced in gene-level analysis highlighting potential shared biological mechanisms. In addition, MR shows stronger instrumental estimates of DBP on migraine than SBP. Our results suggest a critical role of DBP in migraine susceptibility and shared biological mechanisms between BP and migraine.

Results

Shared heritability between migraine and blood pressure. There was a positive overall genetic correlation of migraine with DBP ($r_g = 0.11$, Wald test $P = 3.56 \times 10^{-06}$) and SBP ($r_g = 0.06$, Wald test $P = 0.01$), but not PP ($r_g = -0.01$, Wald test $P = 0.75$) using linkage disequilibrium (LD) score regression (LDSC) (Table 1). When extended to the migraine subtypes: migraine with aura (MA) and migraine without aura (MO), DBP was consistently correlated with both MA ($r_g = 0.17$, Wald test $P = 1.50 \times 10^{-03}$) and MO ($r_g = 0.14$, Wald test $P = 1.20 \times 10^{-03}$), whereas SBP was only marginally correlated with MA ($r_g = 0.10$, Wald test $P = 0.04$). Findings for genetic covariance analyzer (GNOVA), which included SNPs with lower minor allele frequency (MAF) than LDSC, were similar with r_g of 0.12 (Wald test $P = 3.45 \times 10^{-07}$), 0.07 (Wald test $P = 4.64 \times 10^{-03}$), and 0.00 (Wald test $P = 0.94$) for DBP, SBP, and PP, respectively (Table 1). Partitioned genetic correlation did not reveal strong contrasts but suggested that shared effects were concentrated in some chromosomes with the

Table 1 Genetic correlation between migraine and blood pressure.

Method	Trait 1	Trait 2	r_g	P^*	gcov	gcov_se
LDSC	Any migraine	DBP	0.11	3.56×10^{-06}	0.018	0.009
		SBP	0.06	0.01	0.004	0.009
		PP	-0.01	0.75	-0.009	0.008
	Migraine with aura	DBP	0.17	1.50×10^{-03}	-0.006	0.008
		SBP	0.10	0.04	-0.014	0.008
		PP	0.00	0.92	-0.015	0.007
	Migraine without aura	DBP	0.14	1.20×10^{-03}	0.014	0.008
		SBP	0.03	0.43	0.010	0.008
		PP	-0.08	0.06	0.002	0.007
GNOVA	Any migraine	DBP	0.12	3.45×10^{-07}	0.009	0.002
		SBP	0.07	4.64×10^{-03}	0.005	0.002
		PP	0.00	0.94	0.000	0.002
	Migraine with aura	DBP	0.15	1.90×10^{-05}	0.008	0.002
		SBP	0.10	2.57×10^{-03}	0.006	0.002
		PP	0.03	0.33	0.002	0.002
	Migraine without aura	DBP	0.13	1.86×10^{-04}	0.008	0.002
		SBP	-0.02	0.66	-0.001	0.002
		PP	-0.12	2.12×10^{-04}	-0.006	0.002

r_g Genetic correlation, gcov genetic covariance, gcov_se standard error of genetic covariance, LDSC LD score regression, GNOVA genetic covariance analyzer, DBP diastolic blood pressure, SBP systolic blood pressure, PP pulse pressure.

* P -value was calculated for the genetic correlation in LDSC and for the genetic covariance in GNOVA, P -values are based on two-sided Wald test.




Fig. 1 Local genetic correlation between migraine and BP traits at reported migraine loci using ρ -HESS and GWAS-PW. Colors represent the significance level of local genetic correlation between migraine and blood pressure (BP) traits (DBP, SBP, and PP) using ρ -HESS ($P_{\rho\text{-HESS}}$ based on Wald test), red for positive genetic correlation and blue for negative genetic correlation at the corresponding locus. Dots represent the estimated posterior probability (PPA₃) that genetic associations with migraine and BP traits (DBP, SBP, and PP) co-localize at the corresponding locus, larger size indicate larger posterior probability. Significant local genetic correlation between BP traits and migraine was observed at three regions: harboring gene *FHL5*, *C7orf10*, and *PLCE1*, after controlling for multiple testing ($P_{\rho\text{-HESS}} < 0.05/1703$, see details in Supplementary Table 1) and with high estimated posterior probability (PPA₃ > 0.9, see details in Supplementary Table 2).

strongest positive genetic correlation observed at chr22 ($r_g = 0.47$, Wald test $P = 1.37 \times 10^{-04}$) between migraine and DBP, and the strongest negative genetic correlation observed at chr19 ($r_g = -0.32$, Wald test $P = 1.28 \times 10^{-03}$) between migraine and PP (Supplementary Figs. 10–21).

The local genomic regions around individual migraine loci from GWAS showed signals of genetic overlap with BP (Fig. 1). Accounting for multiple testing, there was genome-wide significant local genetic correlation between migraine and BP at three regions (chr6: 94441175..97093511 harboring previous migraine locus *FHL5*; chr7: 39862670..42001811 harboring previous migraine locus *C7orf10*; and chr10: 95396368..96221243 harboring previous migraine locus *PLCE1*) using heritability estimation from summary statistics (ρ -HESS) (Fig. 1 and Supplementary Table 1, $P < 0.05/1703$). The genetic correlation between migraine and SBP was negative in the chromosome 7 region despite being positive across the whole genome (Fig. 1). For PP, although the overall genome-wide genetic correlation with migraine was null, there were significant local genetic correlations at chromosome 6 (Wald test $P = 3.20 \times 10^{-06}$) and 7 (Wald test $P = 3.98 \times 10^{-08}$), which were also significantly correlated for the other BP measures. Results were consistent for these regions with the alternative pairwise traits analysis of GWAS (GWAS-PW) approach (i.e. PPA₃ > 0.9, Fig. 1 and Supplementary Table 2).

Taken together, although the overall genetic correlations between BP traits and migraine were relatively modest compared to more closely related phenotypes, e.g. among psychiatric disorders ($r_g \sim 0.6$) or between lipids and CAD ($r_g \sim 0.25$)²², they nevertheless indicate potential shared genetic etiologies, especially at certain chromosomes or regions, and are therefore worthy of additional investigation into potential mechanisms using cross-trait analysis and expression-trait analysis.

Cross-trait meta-analysis of migraine with BP measurements.

We conducted cross-trait meta-analysis to identify individual SNPs that may share association with BP and migraine using the Cross Phenotype Association (CPASSOC) package. Thirty-three independent loci reached genome-wide significance for combined statistics ($P_{\text{CPASSOC}} \leq 5 \times 10^{-08}$) and suggestive trait-specific significance ($P_{\text{GWAS}} \leq 1 \times 10^{-05}$) for migraine and at least one BP

measurement (Supplementary Tables 3–5), 19 of which were previously reported migraine loci, including *PHACTR1*, *LRP1*, *FHL5*, *C7orf10*, *MPPED2*, *CFDP1*, and *SLC24A3*. Nine of the remaining 14 shared loci (Table 2) were replicated at nominal significance level in the independent migraine association study using UK Biobank data, and 10 of them were also related with broadly-defined headache ($P < 0.05$, Supplementary Table 6).

Among the candidate migraine loci, lead SNP *rs62155750* was most significant (chr2q11.1, $P_{\text{CPASSOC}} = 5.42 \times 10^{-34}$ for DBP based on S_{Het} statistic). *Rs62155750* was a significant expression quantitative trait locus (eQTL) for its nearby gene *ADRA2B* (Supplementary Table 7), encoding the subtype B of the α_2 -adrenergic receptor that regulates neurotransmitter release from sympathetic nerves and adrenergic neurons in the central nervous system²³. Interestingly, this locus was related to migraine ($P = 0.02$ based on S_{Het} statistic) but not broadly defined headache ($P = 0.55$ based on S_{Het} statistic) in the replication dataset (Supplementary Table 6). The second strongest signal overall was lead SNP *rs1048483* (at chr17p13.3) that was associated with both SBP ($P_{\text{CPASSOC}} = 9.29 \times 10^{-27}$ based on S_{Het} statistic) and PP ($P_{\text{CPASSOC}} = 5.13 \times 10^{-28}$ based on S_{Het} statistic). *Rs1048483* mapped to *SMG6* that encodes a nonsense-mediated mRNA decay factor, and is a significant eQTL for the nearby gene *SSR* (Serine Racemase, Supplementary Table 8), which is responsible for transforming L-serine to D-serine, a key co-agonist with glutamate at N-methyl-D-aspartate (NMDA) receptors²⁴. Lead SNP *rs6438857* (at chr3q21.2, $P_{\text{CPASSOC}} = 2.64 \times 10^{-22}$, 1.77×10^{-23} , 2.55×10^{-14} for DBP, SBP, and PP, respectively based on S_{Het} statistic) implicating *ITGB5* was the only locus that was shared between migraine and all the three BP measurements. *ITGB5* encodes a beta subunit of integrin (integrin alpha-V/beta-5), which is a member of integrin family of heterodimeric transmembrane cell surface receptors and has a role in vascular permeability induced by vascular endothelial growth factor (VEGF) in the systemic circulation²⁵. *COL4A1* at chr13q34 was shared between migraine and DBP (lead SNP *rs13260*, $P_{\text{CPASSOC}} = 8.69 \times 10^{-15}$ based on S_{Het} statistic) as well as PP (lead SNP *rs12875271*, $P_{\text{CPASSOC}} = 6.29 \times 10^{-12}$ based on S_{Het} statistic). *COL4A1* encodes a type IV collagen alpha protein, and *COL4A1* mutations may present with small vessel disease and stroke, both

Table 2 Candidate migraine loci from cross-trait meta-analysis between migraine and blood pressure using CPASSOC.

Trait 1	Trait 2	SNP	POS	A1	A2	MAF	Trait 1		Trait 2		P _{CPASSOC}	Genes
							BETA	P	BETA	P		
Any migraine	DBP	rs72663521	chr1p34.3	A	G	0.19	0.04	1.94 × 10 ⁻⁰⁶	0.13	1.42 × 10 ⁻⁰⁸	2.22 × 10 ⁻¹²	BMP8A, KIAA0754, MACF1, PABPC4, PPIEL, SNORA55
		rs3766694	chr1q25.1	T	C	0.39	-0.03	1.26 × 10 ⁻⁰⁶	0.11	4.07 × 10 ⁻¹⁰	3.17 × 10 ⁻¹⁴	KIAA0040
		rs62155750	chr2q11.1	A	G	0.31	0.04	4.42 × 10 ⁻⁰⁷	-0.22	8.27 × 10 ⁻²⁹	5.42 × 10 ⁻³⁴	ADRA2B, ARIDA5, ASTL, CIAO1, CNNM4, DUSP2, FAHD2A, FAHD2CP, FER1L5, GPAT2, ITPRIPL1, KANSL3, KCNIP3, LINCO0342, LMAN2L, NCAPH, NEURL3, PROM2, SNRNP200, STARD7, STARD7-AS1, TMEM127, TRIM43, TRIM43B
SBP	DBP	rs6438857	chr3q21.2	T	C	0.43	-0.03	8.92 × 10 ⁻⁰⁷	0.15	1.50 × 10 ⁻¹⁷	2.64 × 10 ⁻²²	ITGB5, KALRN, MUC13, UMPS
		rs6881648	chr5q13.3	A	C	0.37	-0.04	4.76 × 10 ⁻⁰⁷	-0.17	5.06 × 10 ⁻²¹	3.43 × 10 ⁻²⁶	ANKKDD1B, ANKRD31, COL4A3BP, HMGCR, POC5, POLK
		rs1271309	chr12q24.31	A	G	0.17	-0.04	8.56 × 10 ⁻⁰⁶	-0.20	1.45 × 10 ⁻¹⁶	2.04 × 10 ⁻²⁰	FAM101A, MIR6880, NCOR2, ZNF664-FAM101A
SBP	DBP	rs13260	chr13q34	T	G	0.09	0.06	6.60 × 10 ⁻⁰⁷	-0.20	1.66 × 10 ⁻¹⁰	8.69 × 10 ⁻¹⁵	COL4A1
		rs8008129	chr14q23.1	T	C	0.34	0.03	3.91 × 10 ⁻⁰⁶	0.09	1.37 × 10 ⁻⁰⁶	7.22 × 10 ⁻¹⁰	ACTR10, ARIDA4, FLJ13106, PSMA3
		rs28451064	chr21q22.11	A	G	0.13	-0.06	2.69 × 10 ⁻⁰⁷	0.13	1.54 × 10 ⁻⁰⁶	1.96 × 10 ⁻¹⁰	Intergenic near MRPS6
PP	DBP	rs6438857	chr3q21.2	T	C	0.43	-0.03	8.92 × 10 ⁻⁰⁷	0.27	3.13 × 10 ⁻¹⁹	1.77 × 10 ⁻²³	ITGB5, KALRN, MUC13, UMPS
		rs974819	chr11q22.3	T	C	0.29	-0.03	1.00 × 10 ⁻⁰⁵	0.11	4.15 × 10 ⁻⁰⁷	1.67 × 10 ⁻¹⁰	DPH1, HIC1, LOC101927839, MIR132, MIR212, OVCA2, MIR132, MIR212, OVCA2
		rs12875271	chr13q34	A	G	0.09	-0.06	5.15 × 10 ⁻⁰⁷	-0.19	1.18 × 10 ⁻⁰⁷	6.29 × 10 ⁻¹²	COL4A1
PP	DBP	rs28577186	chr16p13.3	A	G	0.35	-0.04	1.44 × 10 ⁻⁰⁶	-0.14	8.39 × 10 ⁻¹⁰	3.77 × 10 ⁻¹⁴	C16orf96, CDPI1, CORO7, CORO7-PAM16, DNAJA3, HMOX2, MGRN1, NMRAL1, PAM16, UBALDI, VASN
		rs1048483	chr17p13.3	T	C	0.49	-0.03	1.31 × 10 ⁻⁰⁶	-0.20	1.47 × 10 ⁻²²	5.13 × 10 ⁻²⁸	DPH1, HIC1, LOC101927839, MIR132, MIR212, OVCA2
		rs1800470	chr19q13.2	A	G	0.40	0.04	4.97 × 10 ⁻⁰⁷	-0.15	1.76 × 10 ⁻¹²	1.49 × 10 ⁻¹⁷	RTN4RL1, SMG6, SRR, TSRT1, ATP5SL, B3GNT8, B9D2, BCKDHA, EXOSC5, TGFBI, TMEM91
rs9982601	chr21q22.11	T	C	0.13	-0.05	1.78 × 10 ⁻⁰⁷	-0.21	7.51 × 10 ⁻¹²	3.38 × 10 ⁻¹⁷	Intergenic near MIRPS6		

Position is under build 37/hg19. All these loci were candidate genes to migraine with genome-wide significant ($P < 5 \times 10^{-8}$) for cross-trait meta-analysis (using heterogeneous version of CPASSOC, SHet) and $P < 1 \times 10^{-5}$ for single trait GWAS. P-values are based on S_{Het} statistic. POS position, MAF minor allele frequency, DBP diastolic blood pressure, SBP systolic blood pressure, PP pulse pressure.

of which also have migraine as a clinical feature^{26,27}. *TGFB1* at chr19q13.2 (lead SNP *rs1800470*, $P_{CPASSOC} = 1.49 \times 10^{-17}$ based on S_{Het} statistic) was shared between migraine and PP alone and encodes a transforming growth factor-beta 1 protein (TGF- β 1) family member.

Cross-trait meta-analysis between migraine subtypes (MA and MO) and BP showed that previous reported migraine loci, including *PHACTRI*, *LRP1*, and *FHL5*, were shared between both migraine subtypes and BP while locus *rs4141663* implicating *ITGB5* was genome-wide significant in cross-trait meta-analysis between MO and BP measurements, but not MA (Supplementary Tables 9–14).

Transcriptome-wide association studies. We performed TWAS to identify gene-level genetic overlap between BP and migraine. There were 76 TWAS genes that were transcriptome-wide significant for both migraine and at least one BP trait, most of which were identified from gene expression in tissues of cardiovascular and nervous system (Fig. 2). Restricting this list to shared genes with independent signals (see Methods), we identified 23 genes that were TWAS significant for both migraine and at least one of the BP traits from tissues including artery, nerve, skin, esophagus mucosa, and whole blood (Supplementary Tables 15–17), among which 12 were migraine candidate genes. Five of these 12 genes were also identified by the cross-trait meta-analysis (*ITGB5*, *SMG6*, *ADRA2B*, *ANKK1B*, and *KIAA0040*). *ITGB5*, *SMG6*, and *ADRA2B* are described above. Data on *ANKK1B* and *KIAA0040* were limited, but *ANKK1B* was previously suggested to have a shared role between migraine and major depressive disorder (MDD)²⁸. Other gene-level genetic overlap between migraine and BP included genes (*CISD2*, *DMPK*, and *C12orf5*) that were related to regulation of calcium homeostasis and reactive oxygen species (ROS)^{29,30}. TWAS genes with independent effects shared by subtypes of migraine and BP were consistent with findings for overall migraine at *ITGB5*, while identifying additional associations at *HMOX2* for MA and

BP, and *HVCN1* and *MANBA* for MO and BP (Supplementary Figs. 22–27, Supplementary Tables 18–23).

Instrumental variable analysis. Finally, we used bi-directional MR instrumental analysis to develop evidence for causality in the relationship between BP and migraine. Genetically instrumented elevated DBP and SBP, and decreased PP were associated with increased risk of having migraine with odds ratios (OR) of 1.20 (95% confidence interval [CI] = 1.15–1.25; Wald test $P = 5.01 \times 10^{-24}$) and 1.05 (95% CI = 1.03–1.07; Wald test $P = 2.34 \times 10^{-06}$) per 10 mmHg increment of DBP and SBP, and 1.09 (95% CI = 1.05–1.14; Wald test $P = 3.29 \times 10^{-06}$) per 10 mmHg decrement of PP (Table 3). There were also significant instrumental variable estimates from migraine to BP. Reverse MR showed significant negative instrumental effects per doubling odds of migraine on SBP (estimate = 0.67 mmHg decrement, Wald test $P = 1.01 \times 10^{-10}$) and PP (estimate = 0.55 mmHg decrement, Wald test $P = 3.21 \times 10^{-15}$), but not DBP (estimate = 0.08 mmHg decrement, Wald test $P = 0.45$). All heterogeneity P -values were non-significant ($P_{HEIDI} > 0.01$) indicating at worst only subtle heterogeneity among retained instruments. In conditional analysis to distinguish effects mediated by DBP from those mediated by SBP, there was an increase in the instrumental association of high DBP on migraine with conditioning on SBP (OR [95% CI] = 1.38 [1.30–1.46], Wald test $P = 4.16 \times 10^{-37}$), while an opposite effect of high SBP on migraine with conditioning on DBP (OR [95% CI] = 0.86 [0.83–0.90], Wald test $P = 2.08 \times 10^{-22}$). The diverging instrumental effects of DBP and SBP on migraine were also supported by restricting analysis to SNP instruments that were non-significant ($P > 0.05$) for one measure but highly significant ($P < 1 \times 10^{-5}$) for the other (Supplementary Fig. 28). For significance thresholds of $P < 5 \times 10^{-8}$ or smaller, the instrumental effects of DBP and SBP for migraine were associated respectively with increased and decreased migraine susceptibility. The instrumental variable analysis revealed consistent associations of




Fig. 2 Number of shared TWAS significant genes between migraine and BP traits across 48 GTEx tissues (version 7). The X axis shows the count of genes from tissues in the GTEx database meeting significance thresholds for multiple testing for migraine and for each of the BP measures as indicated. The Y axis lists GTEx tissues. Colors represent different tissue categories. The null hypothesis of TWAS is no expression-trait association (or genetic correlation between expression and a trait) conditional on the observed GWAS statistics at the corresponding locus. The total number of TWAS gene-tissue pairs being tested is 206,397 across 48 GTEx tissues. TWAS transcriptome-wide association studies, BP blood pressure, DBP diastolic blood pressure, SBP systolic blood pressure, PP pulse pressure, No. number.

Table 3 Bi-directional instrumental estimates between migraine and blood pressure using GSMR.

Exposure	Outcome	Covariates	Direction	Instrumental estimates ^a	se	P-Bonferroni
DBP	Any migraine	—	Forward	0.18	0.02	5.01×10^{-24}
			Reverse	-0.11	0.07	0.45
	MA	—	Forward	0.12	0.05	0.18
			Reverse ^b			
MO	Reverse ^b	—	Forward	0.29	0.05	1.24×10^{-09}
			Reverse			
SBP	Any migraine	—	Forward	0.05	0.01	2.34×10^{-06}
			Reverse	-0.97	1.01×10^{-10}	
MA	—	Forward	0.04	0.03	1.00	
		Reverse ^b				
MO	Reverse ^b	Forward	Forward	0.06	0.36	
			Reverse			
PP	Any migraine	—	Forward	-0.09	0.02	3.29×10^{-06}
			Reverse	-0.79	3.21×10^{-15}	
MA	—	Forward	-0.06	0.05	1.00	
		Reverse ^b				
MO	Reverse ^b	Forward	Forward	-0.15	5.80×10^{-03}	
			Reverse			
Conditional GSMR ^c						
DBP	Any migraine	SBP	Forward	0.32	0.03	4.16×10^{-37}
SBP	Any migraine	DBP	Forward	-0.15	0.02	2.08×10^{-22}

GSMR Generalized summary-data-based Mendelian randomization, se standard error, DBP diastolic blood pressure, SBP systolic blood pressure, PP pulse pressure, MA migraine with aura, MO migraine without aura.

P-values are based on two-sided Wald test and used Bonferroni correction.

^aThe instrumental estimate is corresponding to 10 mmHg increment of blood pressure for the forward direction.

^bToo few instruments to conduct reverse GSMR for migraine with aura and without aura (number of genome-wide significant index SNPs <10).

^cConditional GSMR was performed by conditioning the exposure on the corresponding covariates (using mtCOJO, <https://cns.genomics.com/software/gcta/#mtCOJO>) and then using the conditioned summary statistics to infer the instrumental estimates from the exposure to the outcome.

elevated DBP and decreased PP with MO (OR [95% CI] = 1.34 [1.21–1.47], Wald test $P = 1.24 \times 10^{-09}$, OR [95% CI] = 1.16 [1.05, 1.28], Wald test $P = 5.80 \times 10^{-03}$, respectively), whereas no significant association was observed for MA after controlling for multiple testing (Table 3). Sensitivity analysis for the main MR analysis using inverse-variance weighted (IVW), weighted median, simple median, and MR-Egger procedures suggested there was no systematic bias due to pleiotropy (Supplementary Table 24), and MR-Steiger results showed that all the causal estimates were oriented in the intended direction (all $P_{\text{MR-Steiger}} < 0.05$). Taken together, the instrumental analyses suggest a potential causal role of elevated DBP on migraine susceptibility, whereas conditional on DBP, SBP may be causally protective. These relationships are also reflected in a potential inverse causal relationship between PP and migraine.

We also applied MR to explore the potential role of causality in anti-hypertensives for migraine prophylaxis effect by only examining lead variants in targets of BP-lowering medications (i.e. beta blocker: *ADRB1*, ACE inhibitor: *ACE*, calcium channel blockers: *CACNB2*, *CACNA1D*, and *CACNA1C*)³¹. Instrumental associations at these SNPs were directionally consistent with the preceding findings but none was significant alone or in combination (all $P > 0.05$), nor was any SNP strongly associated with migraine alone (all $P > 0.01$) (Supplementary Table 25).

When applied to two cardiovascular comorbidities of migraine, stroke and CAD, the instrumental methods suggested a prominent role for SBP rather than DBP (Table 4). Although both SBP and DBP were strongly associated with all stroke subtypes in the primary analysis, conditioning by SBP attenuated the DBP effect for all stroke subtypes except for large artery stroke (LAS), for which there was a significant inverse DBP association. After conditioning

on DBP, SBP remained significantly associated with any stroke, ischemic stroke, large artery stroke, and small vessel stroke. Similarly, after conditioning on DBP, SBP was positively associated with CAD, but DBP conditioned on SBP had an inverse association. In sensitivity analysis restricted to SNP instruments that were significant ($P < 1 \times 10^{-5}$) for one BP trait but non-significant for the other ($P > 0.05$), SBP was inferred to have stronger effects than DBP on CAD and LAS, for which the effect of DBP was protective as observed in the conditional analysis (Supplementary Fig. 29). For the other stroke outcomes, effects of SBP were stronger than or comparable to effects of DBP, especially when using stronger SNP instruments.

Discussion

The conclusions from our genetic analyses were highly consistent and generally support observational associations of positive correlation between BP and migraine³² but also qualify these associations in important ways. We find the strongest association between elevated DBP and increased migraine susceptibility. Weaker genetic relationships of elevated SBP with migraine were largely explained by effects on DBP, and conditional on DBP, genetically determined SBP was inversely related to migraine susceptibility. The latter relationship was supported by SNP instruments exclusively associated with SBP and the reverse direction instrumental variable analysis. Consistent with distinct effects of SBP and DBP, greater genetically determined PP was strongly associated with less susceptibility to migraine in the instrumental variable analysis. Because we leveraged germline genetic variation as instrumental variables from large independent studies, our causal estimates will be less affected by reverse causation and possibly also selection bias than inference about

Table 4 Instrumental estimates between blood pressure and cardiovascular diseases (stroke and CAD) using GSMR.

Exposure	Outcome	Direction	GSMR ^a			Conditional GSMR ^b			
			Instrumental estimates	se	P	Covariates	Instrumental estimates	se	P
DBP	AS	Forward	0.50	0.03	1.82E-47	SBP	-0.04	0.03	0.24
SBP		Forward	0.31	0.02	9.49E-61	DBP	0.13	0.02	1.04E-12
DBP	IS	Forward	0.49	0.04	1.36E-38	SBP	-0.1	0.03	3.05E-03
SBP		Forward	0.30	0.02	2.36E-51	DBP	0.19	0.02	4.10E-22
DBP	LAS	Forward	0.59	0.09	9.90E-11	SBP	-0.67	0.08	1.10E-15
SBP		Forward	0.56	0.05	6.28E-30	DBP	0.49	0.05	2.70E-25
DBP	CES	Forward	0.27	0.07	9.67E-05	SBP	0.01	0.06	0.84
SBP		Forward	0.17	0.04	4.36E-06	DBP	0.06	0.04	0.10
DBP	SVS	Forward	0.75	0.09	2.11E-18	SBP	0.12	0.08	0.12
SBP		Forward	0.39	0.05	2.62E-17	DBP	0.17	0.04	6.65E-05
DBP	CAD	Forward	0.59	0.04	3.69E-58	SBP	-0.19	0.03	2.83E-08
SBP		Forward	0.34	0.02	3.87E-71	DBP	0.2	0.02	6.56E-26

GSMR Generalized summary-data-based Mendelian randomization, se standard error, DBP diastolic blood pressure, SBP systolic blood pressure, AS any stroke, IS ischemic stroke, LAS large artery stroke, CES cardioembolic stroke, SVS small vessel stroke, CAD coronary artery disease. P-values are based on two-sided Wald test.

^aThe instrumental estimate is corresponding to 10 mmHg increment of blood pressure on the corresponding outcome.

^bConditional GSMR was performed by conditioning the exposure on the corresponding covariates (using mtCOJO, <https://cnsgenomics.com/software/gcta/#mtCOJO>) and then use the conditioned summary statistics to infer the instrumental estimates from the exposure to the outcome.

relationships between BP and migraine from observational epidemiology^{33,34}. In fact, the findings from genetics are concordant with at least one of the prior observational studies⁸.

Meanwhile, 9 replicating SNPs from cross-trait association analysis as well as 12 genes from TWAS of both migraine and BP suggested potential functions relevant to migraine. The five loci identified in both SNP and TWAS analysis revealed potential shared biological mechanisms in migraine and BP regulation involving vascular development and endothelial function, neurogenic inflammation, calcium homeostasis through proteins encoded by *ITGB5*, *SMG6*, *ADRA2B*, *ANKK1*, and *KIAA0040* and, in particular, functions of the α 2-adrenergic receptor type B encoded by *ADRA2B*. Neurotransmitters, such as glutamate, serotonin (5-HT), dopamine (DA), noradrenalin (NE), substance P, and calcitonin gene-related peptide (CGRP), have all been identified as contributing causally to migraine³⁵, as well as potential therapeutic targets^{36,37}, and all are related with the α 2-adrenergic receptor regulation³⁸. Therefore, our results support the role of α 2-adrenergic receptor in migraine mechanisms.

In contrast to the results for the genetic effects of DBP and PP on migraine, the genetic association between BP and cardiovascular events was driven by SBP, consistent with the results from observational studies³⁹. This suggests that different mechanisms may underlie BP associations with migraine compared to CVD. Thus, observational associations of migraine with cardiovascular events likely do not involve BP-based etiology in a trivial way, a conclusion further supported by the larger MR effects of BP on cardiovascular events compared to the MR effects of BP on migraine. However, it is also possible that potential genetic heterogeneity in migraine or misclassification due to changes in migraine presentation over time may have attenuated the MR association between BP and migraine³.

This study comprehensively investigates the genetic-based association between migraine and BP. The main strengths of our study include large-scale genetic data (sample size up to 757,601), independent replication of migraine candidate loci from cross-trait meta-analysis, the use of multiple MR sensitivity analysis for outliers, horizontal pleiotropy, and reverse causation, and the use of exclusive SNP instruments for DBP or SBP that were significant for one trait ($P < 1.00 \times 10^{-5}$) but non-significant ($P > 0.05$) for the other. However, we acknowledge limitations. First, our conclusions are limited to a general susceptibility of migraine and its major subtypes MA and MO but may not extend to

different migraine traits over time or forms of migraine that may not arise from the common, population-based genetic susceptibilities implicit in our datasets, e.g. familial forms of migraine. Second, although the instrumental analysis focused on genetic variation in targets of BP-lowering medications (beta blocker, ACE inhibitor, and calcium channel blocker) was not significant, it may also have been underpowered. Based on the combined effects of SNPs in these genes on BP, we estimated there was only <50% power at nominal significance to detect such instrumental effects on migraine in our datasets⁴⁰. Third, although our analysis points to tissues and genes relevant to migraine susceptibility and BP, more work is needed to identify individual cell types and more detailed molecular mechanisms with the goal of developing potential therapeutic strategies.

Nevertheless, the findings further our understanding of the long-standing debate about the role of BP in migraine susceptibility, reveal the prominent genetic-based role of DBP in migraine susceptibility, and identify shared genetic components including *ADRA2B*, all of which may provide insight into future migraine therapies.

Methods

Summary statistics from GWAS for migraine and blood pressure. We used the most recent GWAS summary-level data from International Headache Genetics Consortium (IHGC) for migraine (any migraine and two subtypes of migraine: migraine with aura [MA] and migraine without aura [MO]) and from the International Consortium of Blood Pressure-Genome Wide Association Studies (ICBP) and UK Biobank (UKB) for three BP traits (SBP, DBP, and PP)^{3,41}. The migraine meta-analysis summary statistics combined 59,674 cases and 316,078 controls from 22 cohort level GWASs³, whereas the BP meta-analysis summary statistics combined 757,601 participants from the UKB ($N = 458,577$) and ICBP ($N = 299,024$ across 77 cohorts)⁴¹. In the original GWASs, migraine and its two sub-forms (MA and MO) were defined by diagnostic criteria from the International Headache Society and the summary statistics were adjusted for age, sex, and principle components where applicable in each sub-cohort³, whereas BP summary statistics (including three traits: SBP, DBP, and PP) were adjusted for age, age², sex, and body mass index (BMI) in the parent study, and all sub-cohorts corrected for hypertension treatment ($+15/10$ mmHg in the presence of any hypertensive medication)⁴¹. All of the participants were of European descent with only a small fraction of overlapping samples ($N = 39,199$, proportion of overlapping samples is ~10% for migraine summary statistics, and ~5% for BP summary statistics) between migraine and BP traits. Analysis in the current study was restricted to SNPs, at most ~7 million, which were common to GWASs for migraine and the BP traits. To compare the instrumental effects of BP traits on migraine and two migraine cardiovascular comorbidities, coronary artery disease (CAD) and stroke, we used publicly available GWAS summary statistics from European descent individuals for CAD and stroke from CARDIoGRAM and MEGASTROKE, respectively^{42,43}. To minimize the bias from overlapping samples when conducting the instrumental analyses of BP with CAD and stroke, we used BP GWAS

summary statistics ($N = 361,194$) from the UK Biobank, which is publicly available at <http://www.nealelab.is/uk-biobank/>⁴⁴. All participants provided written informed consent to each of the sub-cohort of the consortium.

Genetic correlation analysis. To evaluate genetic correlation between migraine and BP, we used conventional cross-trait linkage disequilibrium (LD) score regression (LDSC)¹⁷ and the more recent genetic covariance analyzer (GNOVA)⁴⁵. For LDSC, we used precomputed LD-scores derived from ~1.2 million common- and well-imputed SNPs in European populations as represented in the Hapmap3 reference panel excluding the HLA region¹⁷. With GNOVA, which is potentially more powerful than LDSC⁴⁵, we estimated the genetic correlation across ~5 million well-imputed SNPs in the 1000 Genomes Project and partitioned the estimates among categories of SNPs defined by 11 functional categories⁴⁶, quartiles of MAF, and regions implicated in transcription for seven broadly-defined tissue types⁴⁵. Both LDSC and GNOVA controlled for potential overlapping samples between each pair of traits^{17,45}.

Local genetic correlation. We estimated local genetic correlations between migraine and BP traits in 1703 pre-specified LD-independent segments with both ρ -HESS¹⁸ and GWAS-PW⁴⁷. Both methods are designed to identify small contiguous regions of the genome in which the genetic associations with two traits are locally concordant. However, they use different approaches. ρ -HESS quantifies the local genetic covariance (and correlation) and P -values ($P_{\rho\text{-HESS}}$) between pairs of traits at local regions¹⁸, whereas GWAS-PW uses a Bayesian framework to estimate the posterior probability (PPA_3) that genetic associations with the two traits co-localize using priors that are learned from the data⁴⁷. BP and migraine were considered to have genetic correlation at local region if $P_{\rho\text{-HESS}}$ was significant after correcting for multiple testing ($P_{\rho\text{-HESS}} < 0.05/1703$) and PPA_3 from GWAS-PW was larger than 0.9.

Cross-trait meta-analysis between migraine and BP traits. We conducted pairwise cross-trait meta-analysis using Cross Phenotype Association (CPASSOC)¹⁹ through the statistic S_{Het} that implements a sample size-weighted, fixed effect meta-analysis of the association statistics from the individual traits while modeling genetic covariance from all sources. In these analyses, we used total sample size values directly from the summary statistics file for BP and an average effective sample size for migraine⁴⁸. The cross-trait meta-analysis was not inflated by observing a mean ratio of (LDSC intercept-1)/(mean(χ^2) - 1) at 0.05 (Supplementary Figs. 1–9). Replication of migraine candidate associations from CPASSOC was performed using an independent dataset from UK Biobank (using data from data field 20002 and 6159 for migraine and recent headache, respectively, see details in Supplementary Note 1).

Transcriptome-wide association studies. To identify genes whose expression pattern across tissues implicates etiology or biological mechanisms shared by migraine and the BP measures, we performed TWAS⁴⁹. With TWAS, we compared gene-based models of genetic effects on tissue-specific gene expression from GTEx v.7 for migraine and the BP measures from the GWAS summary statistics to estimate strength of association between concordant gene-based genetic influences on gene expression on migraine or BP. In total, we performed 48 TWASs for each trait, one tissue-trait pair at a time. The null hypothesis of TWAS is no expression-trait association (or genetic correlation between expression and a trait) conditional on the observed GWAS statistics at the locus. In practice, a permutation test based on 1000 resampling iterations was run for each TWAS gene to ensure that the TWAS false positive rate was well controlled⁴⁹. We applied Bonferroni correction to identify significant expression-trait associations adjusted for multiple comparisons for all gene-tissue pairs tested for each trait (~200,000 gene-tissue pairs in total, significant expression-trait associations were defined as $P_{\text{Bonferroni}} < 0.05$), and then identified genes that had Bonferroni significant associations for both migraine and BP. We further tested for conditional relationships among the shared genes to identify an independent set of gene-based genetic models using an extension of TWAS that leverages previous methods for joint/conditional tests of SNPs using summary statistics²⁰ (Supplementary Note 2).

Generalized summary-data-based Mendelian randomization. To examine evidence for potential causal relationships between migraine and BP, we conducted instrumental variable analysis using bi-directional MR implemented in generalized summary-data-based Mendelian randomization (GSMR)²¹. GSMR applies strict criteria to select independent SNP instruments and extends conventional MR by accounting for the sampling variance in the genetic effects on both exposure ($b_{x\text{-}}$) and outcome ($b_{y\text{-}}$) in estimating the instrumental effect. Further, as pleiotropy is an important potential confounder that could bias the estimates and possibly result in an inflated test-statistic in MR, we used heterogeneity criteria in HEIDI (heterogeneity in dependent instruments, $P_{\text{HEIDI}} < 0.01$) in the GSMR package to exclude likely pleiotropic SNPs from the analysis. To evaluate separate effects of SBP and DBP on migraine, we performed conditional instrumental analysis using mtCOJO (multi-trait-based conditional and joint analysis), also within GSMR, with a two-step procedure requiring only the GWAS summary statistics²¹. SNP effects on SBP (y) were adjusted for effects on DBP (x) (or vice-versa) (i.e. b_{xy} obtained from GSMR) in step 1, and then the adjusted instruments were used to derive the conditional instrumental estimate in step 2. P -values were corrected for multiple testing using Bonferroni

criteria. We conducted sensitivity analyses using conventional inverse-variance weighted (IVW) MR, weighted median, simple median, MR-egger (Egger regression), and MR-Steiger (Supplementary Note 3). As migraine is a binary variable, we interpreted the reverse causal estimates as the average change in BP per doubling (twofold increase) in the odds of migraine, which could be obtained by multiplying the reverse causal estimate by 0.693 (\log_2)⁵⁰.

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

Summary-level data for CAD (CARDIoGRAM), Stroke (MEGASTROKE), and BP (International Consortium of Blood Pressure genetics [ICBP]) and the UK Biobank [UKB]) are publicly available at: <http://www.cardiogramplus4d.org/data-downloads/> and <http://www.megastroke.org/download.html>; and <http://www.nealelab.is/uk-biobank/>. Summary-level data ($P < 1 \times 10^{-5}$) from International Headache Genetics Consortium (IHGC) for migraine are available here: <http://www.headachegenetics.org/content/datasets-and-cohorts>. Individual level data from the UK Biobank (UKB) are available upon application: <https://www.ukbiobank.ac.uk/>.

Received: 16 December 2019; Accepted: 2 June 2020;

Published online: 06 July 2020

References

1. Disease, G. B. D., Injury, I. & Prevalence, C. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* **390**, 1211–1259 (2017).
2. Kurth, T., Gaziano, J. M., Cook, N. R., Logroscino, G., Diener, H. C. & Buring, J. E. Migraine and risk of cardiovascular disease in women. *JAMA* **296**, 283–291 (2006).
3. Gormley, P. et al. Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. *Nat. Genet.* **48**, 856–866 (2016).
4. Debette, S. et al. Common variation in PHACTR1 is associated with susceptibility to cervical artery dissection. *Nat. Genet.* **47**, 78–83 (2015).
5. Winsvold, B. S. et al. Genetic analysis for a shared biological basis between migraine and coronary artery disease. *Neurol. Genet.* **1**, e10 (2015).
6. Scher, A. I., Terwindt, G. M., Picavet, H. S., Verschuren, W. M., Ferrari, M. D. & Launer, L. J. Cardiovascular risk factors and migraine: the GEM population-based study. *Neurology* **64**, 614–620 (2005).
7. Sacco, S., Pistoia, F., Degan, D. & Carolei, A. Conventional vascular risk factors: their role in the association between migraine and cardiovascular diseases. *Cephalalgia* **35**, 146–164 (2015).
8. Hagen, K., Stovner, L. J., Vatten, L., Holmen, J., Zwart, J. A. & Bovim, G. Blood pressure and risk of headache: a prospective study of 22 685 adults in Norway. *J. Neurol. Neurosurg. Psychiatry* **72**, 463–466 (2002).
9. Tronvik, E., Stovner, L. J., Hagen, K., Holmen, J. & Zwart, J. A. High pulse pressure protects against headache: prospective and cross-sectional data (HUNT study). *Neurology* **70**, 1329–1336 (2008).
10. Tzourio, C., Gagniere, B., El Amrani, M., Alperovitch, A. & Bousser, M. G. Relationship between migraine, blood pressure and carotid thickness. A population-based study in the elderly. *Cephalalgia* **23**, 914–920 (2003).
11. Gudmundsson, L. S., Thorgeirsson, G., Sigfusson, N., Sigvaldason, H. & Johannsson, M. Migraine patients have lower systolic but higher diastolic blood pressure compared with controls in a population-based study of 21,537 subjects. The Reykjavik Study. *Cephalalgia* **26**, 436–444 (2006).
12. Rist, P. M., Winter, A. C., Buring, J. E., Sesso, H. D. & Kurth, T. Migraine and the risk of incident hypertension among women. *Cephalalgia* **38**, 1817–1824 (2018).
13. Entonen, A. H. et al. Migraine predicts hypertension—a cohort study of the Finnish working-age population. *Eur. J. Public Health* **24**, 244–248 (2014).
14. Fagermaes, C. F., Heuch, I., Zwart, J. A., Winsvold, B. S., Linde, M. & Hagen, K. Blood pressure as a risk factor for headache and migraine: a prospective population-based study. *Eur. J. Neurol.* **22**, e110–e151 (2015).
15. Linde, K. & Rosnagel, K. Propranolol for migraine prophylaxis. *Cochrane Database Syst. Rev.* **2**, CD003225 (2004).
16. Jackson, J. L. et al. Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis. *PLoS ONE* **14**, e0212785 (2019).
17. Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).
18. Shi, H., Mancuso, N., Spendlove, S. & Pasaniuc, B. Local genetic correlation gives insights into the shared genetic architecture of complex traits. *Am. J. Hum. Genet.* **101**, 737–751 (2017).

19. Zhu, X. et al. Meta-analysis of correlated traits via summary statistics from GWAS with an application in hypertension. *Am. J. Hum. Genet.* **96**, 21–36 (2015).
20. Gusev, A. et al. Transcriptome-wide association study of schizophrenia and chromatin activity yields mechanistic disease insights. *Nat. Genet.* **50**, 538–548 (2018).
21. Zhu, Z. et al. Causal associations between risk factors and common diseases inferred from GWAS summary data. *Nat. Commun.* **9**, 224 (2018).
22. Cross-Disorder Group of the Psychiatric Genomics Consortium, et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. *Nat. Genet.* **45**, 984–994 (2013).
23. Supowit, S. C., Hallman, D. M., Zhao, H. & DiPette, D. J. Alpha 2-adrenergic receptor activation inhibits calcitonin gene-related peptide expression in cultured dorsal root ganglia neurons. *Brain Res.* **782**, 184–193 (1998).
24. Mothet, J. P. et al. D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. *Proc. Natl Acad. Sci. USA* **97**, 4926–4931 (2000).
25. Eliceiri, B. P. et al. Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling. *J. Cell Biol.* **157**, 149–160 (2002).
26. Plaisier, E. & Ronco, P. COL4A1-Related Disorders. In: *GeneReviews ((R)) [Internet]* (University of Washington, Seattle; 1993–2020) (2009 Jun 25 [updated 2016 Jul 7]).
27. Lanfranconi, S. & Markus, H. S. COL4A1 mutations as a monogenic cause of cerebral small vessel disease: a systematic review. *Stroke* **41**, e513–e518 (2010).
28. Yang, Y. et al. Molecular genetic overlap between migraine and major depressive disorder. *Eur. J. Hum. Genet.* **26**, 1202–1216 (2018).
29. Yin, P., Anttila, V., Siewert, K. M., Palotie, A., Davey Smith, G. & Voight, B. F. Serum calcium and risk of migraine: a Mendelian randomization study. *Hum. Mol. Genet.* **26**, 820–828 (2017).
30. Cheung, E. C., Ludwig, R. L. & Vousden, K. H. Mitochondrial localization of TIGAR under hypoxia stimulates HK2 and lowers ROS and cell death. *Proc. Natl Acad. Sci. USA* **109**, 20491–20496 (2012).
31. Gill, D. et al. Use of genetic variants related to antihypertensive drugs to inform on efficacy and side effects. *Circulation* **140**, 270–279 (2019).
32. Sodini, S. M., Kemper, K. E., Wray, N. R. & Trzaskowski, M. Comparison of genotypic and phenotypic correlations: Cheverud’s conjecture in humans. *Genetics* **209**, 941–948 (2018).
33. Gkatzionis, A. & Burgess, S. Contextualizing selection bias in Mendelian randomization: how bad is it likely to be? *Int. J. Epidemiol.* **48**, 691–701 (2018).
34. Munafò, M. R., Tilling, K., Taylor, A. E., Evans, D. M. & Davey Smith, G. Collider scope: when selection bias can substantially influence observed associations. *Int. J. Epidemiol.* **47**, 226–235 (2018).
35. Aggarwal, M., Puri, V. & Puri, S. Serotonin and CGRP in migraine. *Ann. Neurosci.* **19**, 88–94 (2012).
36. Charles, A. The pathophysiology of migraine: implications for clinical management. *Lancet Neurol.* **17**, 174–182 (2018).
37. D’Andrea, G. & Leon, A. Pathogenesis of migraine: from neurotransmitters to neuromodulators and beyond. *Neurol. Sci.* **31**, S1–S7 (2010).
38. Fairbanks, C. A., Stone, L. S. & Wilcox, G. L. Pharmacological profiles of alpha 2 adrenergic receptor agonists identified using genetically altered mice and isobolographic analysis. *Pharm. Ther.* **123**, 224–238 (2009).
39. Flint, A. C. et al. Effect of systolic and diastolic blood pressure on cardiovascular outcomes. *N. Engl. J. Med.* **381**, 243–251 (2019).
40. Brion, M. J., Shakhbuzov, K. & Visscher, P. M. Calculating statistical power in Mendelian randomization studies. *Int. J. Epidemiol.* **42**, 1497–1501 (2013).
41. Evangelou, E. et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. *Nat. Genet.* **50**, 1412–1425 (2018).
42. Nelson, C. P. et al. Association analyses based on false discovery rate implicate new loci for coronary artery disease. *Nat. Genet.* **49**, 1385–1391 (2017).
43. Malik, R. et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nat. Genet.* **50**, 524–537 (2018).
44. Neale Lab. Rapid GWAS of thousands of phenotypes for 337,000 samples in the UK Biobank. <http://www.nealelab.is/uk-biobank/> (2017).
45. Lu, Q. et al. A powerful approach to estimating annotation-stratified genetic covariance via GWAS summary statistics. *Am. J. Hum. Genet.* **101**, 939–964 (2017).
46. Finucane, H. K. et al. Partitioning heritability by functional annotation using genome-wide association summary statistics. *Nat. Genet.* **47**, 1228–1235 (2015).
47. Pickrell, J. K., Berisa, T., Liu, J. Z., Segurel, L., Tung, J. Y. & Hinds, D. A. Detection and interpretation of shared genetic influences on 42 human traits. *Nat. Genet.* **48**, 709–717 (2016).
48. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genome-wide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
49. Gusev, A. et al. Integrative approaches for large-scale transcriptome-wide association studies. *Nat. Genet.* **48**, 245–252 (2016).
50. Burgess, S. & Labrecque, J. A. Mendelian randomization with a binary exposure variable: interpretation and presentation of causal estimates. *Eur. J. Epidemiol.* **33**, 947–952 (2018).

Acknowledgements

This research has been conducted using the UK Biobank Resource under Application Number 29273. We would like to thank the participants and researchers from the UK Biobank, 23andMe, Inc., International Headache Genetics Consortium (IHGC), MEGASTROKE, CARDIOGRAM, and International Consortium of Blood Pressure-Genome Wide Association Studies (ICBP) who contributed or collected data. Daniel I. Chasman is funded by US National Institutes of Health and US National Institute of Neurological Disorders and Stroke (R21NS09296 and R21NS104398). Pamela M. Rist is funded by K01 HL128791. The MEGASTROKE project received funding from sources specified at <http://www.megastroke.org/acknowledgments.html>.

Author contributions

Designed the study: Y.G., P.M.R., I.D., and D.I.C.; conducted the analysis: Y.G., P.M.R., F.G., and D.I.C.; interpreted the results: Y.G., P.M.R., I.D., F.G., T.K., and D.I.C.; drafted the manuscript: Y.G., P.M.R., and D.I.C.; made critical revisions to the manuscript: Y.G., P.M.R., I.D., F.G., T.K., and D.I.C.; provided GWAS summary statistics for migraine: The International Headache Genetics Consortium and 23andMe Research Team; and all authors approved the final version of the manuscript.

Competing interests

T.K. reports to have provided methodological expertise to Amgen and CoLucid, for which the Charité – Universitätsmedizin Berlin has received financial compensation. T.K. further received honoraria from Novartis and Daiichi Sankyo for a scientific presentation and from Lilly, Newsenselab, and Total for methodological advice. The remaining authors declare no competing interests.

Additional information


Supplementary information is available for this paper at <https://doi.org/10.1038/s41467-020-17002-0>.

Correspondence and requests for materials should be addressed to Y.G. or D.I.C.

Peer review information *Nature Communications* thanks Guillaume Paré and other, anonymous, reviewers for their contributions to the peer review of this work. Peer review reports are available.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020

The International Headache Genetics Consortium

Padhraig Gormley^{5,6,7,8}, Verner Anttila^{6,7,9}, Bendik S. Winsvold^{10,11,12}, Priit Palta¹³, Tonu Esko^{6,14,15}, Tune H. Pers^{6,15,16,17}, Kai-How Farh^{6,9,18}, Ester Cuenca-Leon^{5,6,7,19}, Mikko Muona^{13,20,21,22}, Nicholas A. Furlotte²³, Tobias Kurth^{24,25}, Andres Ingason²⁶, George McMahon²⁷, Lannie Ligthart²⁸, Gisela M. Terwindt²⁹, Mikko Kallela³⁰, Tobias M. Freilinger^{31,32}, Caroline Ran³³, Scott G. Gordon³⁴, Anine H. Stam²⁹, Stacy Steinberg²⁶, Guntram Borck³⁵, Markku Koironen³⁶, Lydia Quaye³⁷, Hieab H. H. Adams^{38,39}, Terho Lehtimäki⁴⁰, Antti-Pekka Sarin¹³, Juho Wedenoja⁴¹, David A. Hinds²³, Julie E. Buring^{25,42}, Markus Schürks⁴³, Paul M. Ridker^{25,42}, Maria Gudlaug Hrafnisdottir⁴⁴, Hreinn Stefansson²⁶, Susan M. Ring²⁷, Jouke-Jan Hottenga²⁸, Brenda W. J. H. Penninx⁴⁵, Markus Färkkilä³⁰, Ville Arto³⁰, Mari Kaunisto¹³, Salli Vepsäläinen³⁰, Rainer Malik³¹, Andrew C. Heath⁴⁶, Pamela A. F. Madden⁴⁶, Nicholas G. Martin³⁴, Grant W. Montgomery³⁴, Mitja Kurki^{5,6,7}, Mart Kals¹⁴, Reedik Mägi¹⁴, Kalle Pärn¹⁴, Eija Hämäläinen¹³, Hailing Huang^{6,7,9}, Andrea E. Byrnes^{6,7,9}, Lude Franke⁴⁷, Jie Huang⁸, Evie Stergiakouli²⁷, Phil H. Lee^{5,6,7}, Cynthia Sandor⁴⁸, Caleb Webber⁴⁸, Zameel Cader^{49,50}, Bertram Muller-Myhsok⁵¹, Stefan Schreiber⁵², Thomas Meitinger⁵³, Johan G. Eriksson^{54,55}, Veikko Salomaa⁵⁵, Kauko Heikkilä⁵⁶, Elizabeth Loehrer^{38,57}, Andre G. Uitterlinden⁵⁸, Albert Hofman³⁸, Cornelia M. van Duijn³⁸, Lynn Cherkas³⁷, Linda M. Pedersen¹⁰, Audun Stubhaug^{59,60}, Christopher S. Nielsen^{59,61}, Minna Männikkö³⁶, Evelin Mihailov¹⁴, Lili Milani¹⁴, Hartmut Göbel⁶², Ann-Louise Esserlind⁶³, Anne Francke Christensen⁶³, Thomas Folkmann Hansen⁶⁴, Thomas Werge^{65,66,67}, Jaakko Kaprio^{13,68,69}, Arpo J. Aromaa⁵⁵, Olli Raitakari^{70,71}, M. Arfan Ikram^{38,39,71,72}, Tim Spector³⁷, Marjo-Riitta Jarvelin^{36,73,74,75}, Andres Metspalu¹⁴, Christian Kubisch⁷⁶, David P. Strachan⁷⁷, Michel D. Ferrari²⁹, Andrea C. Belin³³, Martin Dichgans^{34,78}, Maija Wessman^{13,20}, Arn M. J. M. van den Maagdenberg^{29,79}, John-Anker Zwart^{10,11,12}, Dorret I. Boomsma²⁸, George Davey Smith²⁷, Kari Stefansson^{26,80}, Nicholas Eriksson²³, Mark J. Daly^{6,7,9}, Benjamin M. Neale^{6,7,9}, Jes Olesen⁶³, Daniel I. Chasman^{25,42}, Dale R. Nyholt⁸¹ & Aarno Palotie^{5,6,7,8,9,13,27,82}

⁵Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. ⁶Medical and Population Genetics Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA. ⁷Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA. ⁸Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK. ⁹Analytic and Translational Genetics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. ¹⁰FORMI, Oslo University Hospital, P.O. 4956 Nydalen, 0424 Oslo, Norway. ¹¹Department of Neurology, Oslo University Hospital, P.O. 4956 Nydalen, 0424 Oslo, Norway. ¹²Institute of Clinical Medicine, University of Oslo, P.O. 1171 Blindern, 0318 Oslo, Norway. ¹³Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland. ¹⁴Estonian Genome Center, University of Tartu, Tartu, Estonia. ¹⁵Division of Endocrinology, Boston Children's Hospital, Boston, MA, USA. ¹⁶Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark. ¹⁷Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark. ¹⁸Illumina, Illumina Way, San Diego, CA 5200, USA. ¹⁹Vall d'Hebron Research Institute, Pediatric Neurology, Barcelona, Spain. ²⁰Folkhälsan Institute of Genetics, FI-00290 Helsinki, Finland. ²¹Neuroscience Center, University of Helsinki, FI-00014 Helsinki, Finland. ²²Research Programs Unit, Molecular Neurology, University of Helsinki, FI-00014 Helsinki, Finland. ²³23andMe, Inc., 223 N Mathilda Ave, Sunnyvale, CA 94086, USA. ²⁴Inserm Research Center for Epidemiology and Biostatistics (U897), University of Bordeaux, 33076 Bordeaux, France. ²⁵Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA 02215, USA. ²⁶deCODE Genetics, 101 Reykjavik, Iceland. ²⁷Medical Research Council (MRC) Integrative Epidemiology Unit, University of Bristol, Bristol, UK. ²⁸Department of Biological Psychology, VU University Amsterdam, 1081 BT Amsterdam, The Netherlands. ²⁹Department of Neurology, Leiden University Medical Centre, PO Box 96002300 RC Leiden, The Netherlands. ³⁰Department of Neurology, Helsinki University Central Hospital, Haartmaninkatu 4, 00290 Helsinki, Finland. ³¹Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Feodor-Lynen-Str. 17, 81377 Munich, Germany. ³²Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany. ³³Department of Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden. ³⁴Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, 300 Herston Road, Brisbane, QLD 4006, Australia. ³⁵Institute of Human Genetics, Ulm University, 89081 Ulm, Germany. ³⁶Center for Life Course Epidemiology and Systems Medicine, University of Oulu, Box 5000FI-90014 Oulu, Finland. ³⁷Department of Twin Research and Genetic Epidemiology, King's College London, London, UK. ³⁸Department of Epidemiology, Erasmus University Medical Center, 3015 CN Rotterdam, The Netherlands. ³⁹Department of Radiology, Erasmus University Medical Center, 3015 CN Rotterdam, The Netherlands. ⁴⁰Department of Clinical Chemistry, Fimlab Laboratories, and School of Medicine, University of Tampere, 33520 Tampere, Finland. ⁴¹Department of Public Health, University of Helsinki, Helsinki, Finland. ⁴²Harvard Medical School, Boston, MA 02115, USA. ⁴³University Duisburg Essen, Essen, Germany. ⁴⁴Landspítali University Hospital, 101 Reykjavik, Iceland. ⁴⁵Department of Psychiatry, VU University Medical Centre, 1081 HL Amsterdam, The Netherlands. ⁴⁶Department of Psychiatry, Washington University School of Medicine, 660 South Euclid, CB 8134, St. Louis, MO 63110, USA. ⁴⁷University Medical Center Groningen, University of Groningen, Groningen, The Netherlands 9700RB. ⁴⁸MRC Functional Genomics Unit, Department of Physiology, Anatomy & Genetics, Oxford University, Oxford, UK. ⁴⁹Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK. ⁵⁰Oxford Headache Centre, John Radcliffe Hospital, Oxford, UK. ⁵¹Max-Planck-Institute of Psychiatry, Munich, Germany. ⁵²Christian Albrechts University, Kiel, Germany. ⁵³Institute

of Human Genetics, Helmholtz Center Munich, Neuherberg, Germany. ⁵⁴Department of General Practice and Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. ⁵⁵National Institute for Health and Welfare, Helsinki, Finland. ⁵⁶Institute of Clinical Medicine, University of Helsinki, Helsinki, Finland. ⁵⁷Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA. ⁵⁸Department of Internal Medicine, Erasmus University Medical Center, 3015 CN Rotterdam, The Netherlands. ⁵⁹Department of Pain Management and Research, Oslo University Hospital, 0424 Oslo, Norway. ⁶⁰Medical Faculty, University of Oslo, 0318 Oslo, Norway. ⁶¹Division of Mental Health, Norwegian Institute of Public Health, P.O. Box 4404 Nydalen 0403 Oslo, Norway. ⁶²Kiel Pain and Headache Center, 24149 Kiel, Germany. ⁶³Danish Headache Center, Department of Neurology, Rigshospitalet, Glostrup Hospital, University of Copenhagen, Copenhagen, Denmark. ⁶⁴Institute of Biological Psychiatry, Mental Health Center Sct. Hans, University of Copenhagen, Roskilde, Denmark. ⁶⁵Institute Of Biological Psychiatry, MHC Sct. Hans, Mental Health Services Copenhagen, 2100 Copenhagen, Denmark. ⁶⁶Institute of Clinical Sciences, Faculty of Medicine and Health Sciences, University of Copenhagen, 2100 Copenhagen, Denmark. ⁶⁷iPSYCH - The Lundbeck Foundation's Initiative for Integrative Psychiatric Research, 2100 Copenhagen, Denmark. ⁶⁸Department of Public Health, University of Helsinki, Helsinki, Finland. ⁶⁹Department of Health, National Institute for Health and Welfare, Helsinki, Finland. ⁷⁰Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, 20521 Turku, Finland. ⁷¹Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, 20521 Turku, Finland. ⁷²Department of Neurology, Erasmus University Medical Center, 3015 CN Rotterdam, The Netherlands. ⁷³Department of Epidemiology and Biostatistics, MRC Health Protection Agency (HPE) Centre for Environment and Health, School of Public Health, Imperial College London, London W2 1PG, UK. ⁷⁴Biocenter Oulu, University of Oulu, Box 500090014 Oulu, Finland. ⁷⁵Unit of Primary Care, Oulu University Hospital, Box 10FIN-90029 Oulu, Finland. ⁷⁶University Medical Center Hamburg Eppendorf, Institute of Human Genetics, 20246 Hamburg, Germany. ⁷⁷Population Health Research Institute, St George's, University of London, Cranmer Terrace, London SW17 0RE, UK. ⁷⁸Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. ⁷⁹Leiden University Medical Centre, Department of Human Genetics, PO Box 96002300 RC Leiden, The Netherlands. ⁸⁰Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland. ⁸¹Statistical and Genomic Epidemiology Laboratory, Institute of Health and Biomedical Innovation, Queensland University of Technology, 60 Musk Ave, Kelvin Grove, QLD 4059, Australia. ⁸²Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.

The 23andMe Research Team

Michelle Agee⁸³, Adam Auton⁸³, Robert K. Bell⁸³, Katarzyna Bryc⁸³, Sarah L. Elson⁸³, Pierre Fontanillas⁸³, Nicholas A. Furlotte⁸³, David A. Hinds⁸³, Karen E. Huber⁸³, Aaron Kleinman⁸³, Nadia K. Litterman⁸³, Jennifer C. McCreight⁸³, Matthew H. McIntyre⁸³, Joanna L. Mountain⁸³, Elizabeth S. Noblin⁸³, Carrie A. M. Northover⁸³, Steven J. Pitts⁸³, J. Fah Sathirapongsasuti⁸³, Olga V. Sazonova⁸³, Janie F. Shelton⁸³, Suyash Shringarpure⁸³, Chao Tian⁸³, Joyce Y. Tung⁸³ & Vladimir Vacic⁸³

⁸³23andMe, Inc., 223 N Mathilda Ave, Sunnyvale, CA 94086, USA.